S
Scohia Pharma
Biotech & Life Sciences · Fujisawa, Japan · Founded 2017
Expanding its strategic partnership with huadong medicine globally for the development of sco-094 MoreLess
Scohia Pharma is a pioneering pharmaceutical company specializing in the development of innovative medicines targeting lifestyle diseases such as diabetes, obesity, and cardiovascular conditions. The company operates in the highly competitive pharmaceutical market, focusing on creating new chemical entities and advancing them through rigorous medicinal evaluation and clinical development processes. Scohia Pharma serves a diverse client base, including healthcare providers, hospitals, and patients who require advanced therapeutic solutions for chronic conditions.
The business model of Scohia Pharma revolves around extensive research and development (R&D) activities, leveraging a team of experienced scientists and researchers with a strong track record in drug development. The company generates revenue through the commercialization of its proprietary drugs, licensing agreements, and strategic partnerships with other pharmaceutical firms. By maintaining a rich development pipeline and focusing on unmet medical needs, Scohia Pharma aims to deliver high-value treatments that improve patient outcomes and quality of life.
Keywords: pharmaceutical, lifestyle diseases, drug development, diabetes, obesity, cardiovascular, R&D, clinical trials, chemical entities, healthcare, innovation.
Company overview
Scohia Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Fujisawa, Japan
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 23.7
Valuation & funding
Scohia Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $31M | $125M | SBI Investment · FRONTEO · Bio-sight Capital · Tohoku University Venture Partners | ↗ |
| SERIES BOther financing | Sep 2024 | $3.7M | $15M | SBI Investment · Tohoku University Venture Partners · Gemseki · SRD Holdings | ↗ |
| CORPORATE SPINOUTOther financing | Apr 2017 | $0 | — | Takeda | — |
| SEEDOther financing | Apr 2017 | $87M | $349M | INCJ · Takeda · Medipal | — |
Growth signals
Scohia Pharma website traffic
Latest recorded traffic for Scohia Pharma is 1.7K monthly website visits, down 55.3% over the last three months.
Comparisons
Scohia Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Scohia Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
14 investors on Scohia Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Scohia Pharma has talent and traffic
team presence
In the news
Latest news about Scohia Pharma
Recent press, funding announcements, and product moves mentioning Scohia Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Scohia Pharma
An AI-synthesized read of the highest-engagement posts about Scohia Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scohia Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.